BioWorld

Aug. 17, 2009

Split Panel Vote Takes Shine off Denosumab: Is PMO Only So-So?

As the dust settled following Thursday's messy panel vote, Amgen Inc.'s much-touted bone drug looked a bit worse for wear. (BioWorld Today) Read More

Clinical Data Driving Biotech's Rebound So Far, BIO Reports

New Evidence for Autoimmunity Connection to Psych Disorders

NewCo News: Treventis has Multiple Targets as It Focuses on Alzheimer's

AGI Loses Axcan as Partner on GERD Drug Omeprazole

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...